List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7854591/publications.pdf

Version: 2024-02-01

		76294	45285
120	8,625	40	90
papers	citations	h-index	g-index
125	125	125	11356
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Right Ventricular Recovery: Early and Late Changes after Acute PE Diagnosis. Seminars in Thrombosis and Hemostasis, 2023, 49, 797-808.	1.5	2
2	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis and Haemostasis, 2022, 122, 131-141.	1.8	55
3	Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. Thrombosis and Haemostasis, 2022, 122, 1061-1070.	1.8	4
4	Off the beaten path: the need for innovation in medical therapy to improve outcomes in acute pulmonary embolism. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 10-12.	0.4	2
5	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials, 2022, 115, 106714.	0.8	3
6	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. Thrombosis Research, 2022, 214, 122-131.	0.8	3
7	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal, 2022, 251, 43-53.	1.2	59
8	Call for Formalized Pathways in VascularÂMedicine Training. Journal of the American College of Cardiology, 2022, 79, 2129-2139.	1.2	3
9	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580.	2.8	11
10	Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy. Journal of Thrombosis and Thrombolysis, 2021, 52, 281-290.	1.0	2
11	Trailblazing in pulmonary embolism research: the importance of extending beyond randomized controlled trials. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 237-239.	0.4	O
12	Thrombophilia, Inflammation, and Recurrent Pregnancy Loss: A Case-Based Review. Seminars in Reproductive Medicine, 2021, 39, 062-068.	0.5	10
13	Recent Randomized Trials of Antithrombotic Therapy for PatientsÂWithÂCOVID-19. Journal of the American College of Cardiology, 2021, 77, 1903-1921.	1.2	150
14	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA - Journal of the American Medical Association, 2021, 325, 1620.	3.8	515
15	Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2021, 52, 1023-1031.	1.0	1
16	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. American Heart Journal, 2021, 235, 12-23.	1.2	36
17	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal of the American College of Cardiology, 2021, 78, 408-411.	1.2	44
18	Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. Human Reproduction, 2021, 36, 2083-2090.	0.4	17

#	Article	IF	CITATIONS
19	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. Circulation: Cardiovascular Imaging, 2021, 14, e012347.	1.3	9
20	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. Journal of the American Heart Association, 2021, 10, e021467.	1.6	4
21	First-in-Human Study to Assess the Safety and Feasibility of the Bashir Endovascular Catheter for the Treatment of Acute Intermediate-Risk Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2021, 14, e009611.	1.4	15
22	Association of ABO blood group type with cardiovascular events in COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 51, 584-586.	1.0	14
23	Reply: The pathway to the †truth†in the study of recurrent pregnancy loss and thrombophilia. Human Reproduction, 2021, 37, 191-193.	0.4	O
24	Thrombophilia, Antithrombotic Therapy, and Recurrent Pregnancy Loss: A Call for Pragmatism in the Face of Unknowns. Seminars in Reproductive Medicine, 2021, 39, 167-169.	0.5	3
25	Case 39-2021: A 26-Year-Old Woman with Respiratory Failure and Altered Mental Status. New England Journal of Medicine, 2021, 385, 2464-2474.	13.9	6
26	Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). European Heart Journal, 2020, 41, 1086-1096.	1.0	35
27	A fortune teller's dream or clinician's nightmare: Right ventricular assessment for risk prediction in pulmonary embolism. Thrombosis Research, 2020, 195, 169-170.	0.8	1
28	Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2548.	3.8	117
29	One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e009012.	1.4	23
30	Advanced Management of Intermediate- and High-Risk Pulmonary Embolism. Journal of the American College of Cardiology, 2020, 76, 2117-2127.	1.2	48
31	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2060-2072.	1.2	230
32	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. American Journal of Medicine, 2020, 133, 1-27.	0.6	18
33	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	1.8	206
34	Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism. Circulation: Cardiovascular Interventions, 2020, 13, e008747.	1.4	8
35	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology, 2020, 75, 2950-2973.	1.2	2,392
36	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars in Thrombosis and Hemostasis, 2020, 46, 908-918.	1.5	13

#	Article	IF	CITATIONS
37	Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation, 2019, 140, e774-e801.	1.6	241
38	Vascular Teams in PeripheralÂVascularÂDisease. Journal of the American College of Cardiology, 2019, 73, 2477-2486.	1.2	32
39	Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). Circulation: Cardiovascular Imaging, 2019, 12, e009903.	1.3	13
40	Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. Journal of Thrombosis and Thrombolysis, 2019, 47, 331-335.	1.0	3
41	A midterm report card for pulmonary embolism response teams. Vascular Medicine, 2018, 23, 72-74.	0.8	11
42	Surgical pulmonary embolectomy and catheter-directed thrombolysis for treatment of submassive pulmonary embolism. Journal of Cardiac Surgery, 2018, 33, 252-259.	0.3	18
43	Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2018, 45, 257-263.	1.0	5
44	A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. Current Emergency and Hospital Medicine Reports, 2018, 6, 54-61.	0.6	3
45	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 2018, 137, 684-692.	1.6	22
46	Oh Heavy Burden: Recognizing the Risk of Venous Thromboembolism in Women Undergoing Assisted Reproduction. Thrombosis and Haemostasis, 2018, 118, 2011-2013.	1.8	9
47	Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. TH Open, 2018, 02, e33-e38.	0.7	7
48	Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. TH Open, 2018, 02, e229-e232.	0.7	2
49	Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. Vascular Medicine, 2018, 23, 388-399.	0.8	24
50	A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism. JACC: Cardiovascular Interventions, 2018, 11, 1401-1410.	1.1	280
51	Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. Vascular, 2017, 25, 54-62.	0.4	6
52	Risk factors for major bleeding in the SEATTLE II trial. Vascular Medicine, 2017, 22, 44-50.	0.8	33
53	Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. Vascular Medicine, 2017, 22, 324-330.	0.8	3
54	Treatment Options in Massive and Submassive Pulmonary Embolism. Cardiology in Review, 2016, 24, 19-25.	0.6	7

#	Article	IF	CITATIONS
55	Underutilization of Anticoagulation for StrokeÂPrevention in AtrialÂFibrillation. Journal of the American College of Cardiology, 2016, 67, 2444-2446.	1.2	22
56	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	0.6	24
57	Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Vascular Medicine, 2016, 21, 361-368.	0.8	15
58	Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 68-80.	1.0	81
59	Multidisciplinary Pulmonary Embolism Response Teams. Circulation, 2016, 133, 98-103.	1.6	129
60	A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. Journal of Visualized Experiments, 2015, , e52761.	0.2	3
61	Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. JAMA Internal Medicine, 2015, 175, 1112.	2.6	84
62	Beyond Virchow's Triad: Does cardiovascular inflammation explain the recurrent nature of venous thromboembolism?. Vascular Medicine, 2015, 20, 102-104.	0.8	16
63	Fat Embolism Syndrome. Circulation, 2015, 131, 317-320.	1.6	105
64	Is Venous Thromboembolism a Chronic Inflammatory Disease?. Clinical Chemistry, 2015, 61, 313-316.	1.5	18
65	Regulatory, legislative, and policy updates with anticoagulant use. Journal of Thrombosis and Thrombolysis, 2015, 39, 273-287.	1.0	O
66	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series ofÂ115ÂPatients. Annals of Thoracic Surgery, 2015, 100, 1245-1252.	0.7	115
67	Mesenteric Venous Thrombosis. Circulation, 2015, 131, 1599-1603.	1.6	56
68	Surgical Pulmonary Embolectomy. Circulation, 2015, 132, 1146-1151.	1.6	18
69	Risk Factors for Venous Thromboembolism: Recognizing the Spectrum of Risk and Understanding the Role of Thrombophilia Testing. , 2015, , 7-14.		O
70	Response to Letter Regarding Article, "Fat Embolism Syndrome― Circulation, 2015, 132, e192.	1.6	0
71	Prevention of Venous Thromboembolism: An Evidence-Based Approach to Thromboprophylaxis. , 2015, , 123-134.		O
72	Handbook for Venous Thromboembolism. , 2015, , .		10

#	Article	IF	CITATIONS
73	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. JACC: Cardiovascular Interventions, 2015, 8, 1382-1392.	1.1	648
74	Pathophysiology of Deep Vein Thrombosis and Pulmonary Embolism: Beyond Virchow's Triad. , 2015, , 15-20.		O
75	Diagnosis of Pulmonary Embolism: An Integrated Approach to Clinical Evaluation, Laboratory Testing, and Imaging., 2015,, 29-39.		O
76	Advanced Therapy for Venous Thromboembolism: Understanding the Role of Systemic Fibrinolysis, Catheter-Based Therapy, and Surgery., 2015,, 51-65.		0
77	Anticoagulation for Venous Thromboembolism: Selecting the Optimal Parenteral and Oral Anticoagulant Regimen., 2015,, 77-91.		O
78	Venous Thromboembolism in Patients With Prior Stroke. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 43-49.	0.7	6
79	Medication Use Evaluation: Pharmacist Rubric for Performance Improvement. Pharmacotherapy, 2014, 34, 5S-13S.	1.2	13
80	Risk Assessment to Predict Arterial and Venous Events in Patients Undergoing Percutaneous Coronary Intervention. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 478-483.	0.7	2
81	Thrombophilia Testing, Recurrent Thrombosis, and Women's Health. Circulation, 2014, 130, 283-287.	1.6	17
82	Hospital Costs of Acute Pulmonary Embolism. American Journal of Medicine, 2013, 126, 127-132.	0.6	103
83	Randomized Trial of Physician Alerts for Thromboprophylaxis after Discharge. American Journal of Medicine, 2013, 126, 435-442.	0.6	25
84	Pulmonary Embolism and Deep Vein Thrombosis. , 2013, , 580-595.		1
85	Submassive Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2013, 309, 171.	3.8	42
86	Venous Thromboembolism in Hospitalized Patients With Active Cancer. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 469-475.	0.7	16
87	Thromboangiitis Obliterans (Buerger's Disease). , 2013, , 533-546.		O
88	Cerebral Venous Thrombosis. Circulation, 2012, 125, 1704-1709.	1.6	117
89	Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. American Journal of Medicine, 2012, 125, 258-264.	0.6	45
90	Venous Thromboembolism in Patients with Diabetes Mellitus. American Journal of Medicine, 2012, 125, 709-716.	0.6	83

#	Article	IF	Citations
91	Venous Thromboembolism in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Medicine, 2012, 125, 1010-1018.	0.6	33
92	Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2011, 364, 351-360.	13.9	325
93	Anticoagulation-associated Adverse Drug Events. American Journal of Medicine, 2011, 124, 1136-1142.	0.6	92
94	Venous Thromboembolism in Heart Failure: Preventable Deaths During and After Hospitalization. American Journal of Medicine, 2011, 124, 252-259.	0.6	42
95	Venous thromboembolism in patients with symptomatic atherosclerosis. Thrombosis and Haemostasis, 2011, 106, 1095-1102.	1.8	26
96	Optimal Duration of Anticoagulation After Venous Thromboembolism. Circulation, 2011, 123, 664-667.	1.6	26
97	Physician alerts to prevent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2010, 30, 1-6.	1.0	15
98	Multi-screen electronic alerts to augment venous thromboembolism prophylaxis. Thrombosis and Haemostasis, 2010, 103, 312-317.	1.8	40
99	Fibrinolysis for acute pulmonary embolism. Vascular Medicine, 2010, 15, 419-428.	0.8	61
100	Thromboangiitis Obliterans. Circulation, 2010, 121, 1858-1861.	1.6	146
101	Adherence to Pharmacological Thromboprophylaxis Orders in Hospitalized Patients. American Journal of Medicine, 2010, 123, 536-541.	0.6	55
102	Management of Submassive Pulmonary Embolism. Circulation, 2010, 122, 1124-1129.	1.6	113
103	Venous Thromboembolism and Atherothrombosis An Integrated Approach. Circulation, 2010, 121, 2146-2150.	1.6	99
104	Venous thromboembolic events in hospitalised medical patients. Thrombosis and Haemostasis, 2009, 102, 505-510.	1.8	57
105	Response to Letter Regarding Article, "Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients― Circulation, 2009, 120, .	1.6	O
106	Physician Alerts to Prevent Symptomatic Venous Thromboembolism in Hospitalized Patients. Circulation, 2009, 119, 2196-2201.	1.6	88
107	Computerized Decision Support for the Cardiovascular Clinician. Circulation, 2009, 120, 1133-1137.	1.6	40
108	Improving Clinical Effectiveness in Thromboprophylaxis for Hospitalized Medical Patients. American Journal of Medicine, 2009, 122, 230-232.	0.6	17

#	Article	IF	CITATIONS
109	Medicare's New Regulations for Deep Vein Thrombosis as a "Never Event†Wise or Worrisome?. American Journal of Medicine, 2009, 122, 975-976.	0.6	10
110	Long-term complications of medical patients with hospitalacquired venous thromboembolism. Thrombosis and Haemostasis, 2009, 102, 688-693.	1.8	59
111	Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. Journal of Thrombosis and Thrombolysis, 2008, 26, 35-40.	1.0	33
112	Heart Failure in Patients With Deep Vein Thrombosis. American Journal of Cardiology, 2008, 101, 1056-1059.	0.7	38
113	Deep-Vein Thrombosis in the Elderly. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 393-398.	0.7	33
114	Pulmonary Embolism in Heart Failure. Circulation, 2008, 118, 1598-1601.	1.6	45
115	Deep vein thrombosis in patients with chronic kidney disease. Thrombosis and Haemostasis, 2008, 99, 1035-1039.	1.8	37
116	Double Trouble for 2,609 Hospitalized Medical Patients Who Developed Deep Vein Thrombosis. Chest, 2007, 132, 554-561.	0.4	87
117	Acute Pulmonary Embolism. Circulation, 2006, 114, e42-7.	1.6	80
118	Acute Pulmonary Embolism. Circulation, 2006, 114, e28-32.	1.6	128
119	Venous Thromboembolism Guidebook. Critical Pathways in Cardiology, 2006, 5, 211-227.	0.2	5
120	The Acutely Decompensated Right Ventricle. Chest, 2005, 128, 1836-1852.	0.4	197